Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

6 inhibitor, a newer drug group which includes Novartis’own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).

Latest news

Lilly gets EMA nod for Verzenio in breast cancer

46% to $3.1bn last year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib).
Novartis considers filings for PI3K drug in breast cancer

own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).
FDA backs earlier use of Lilly’s breast cancer drug Verzenio

year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)).
Novartis bags new breakthrough status for Kisqali in breast cancer

In the study, giving Kisqali (ribociclib) in combination with tamoxifen or an aromatase inhibitor as initial endocrine-based therapy for women in this group significantly prolonged progression-free survival (PFS) compared
NICE backs two advanced breast cancer drugs after price cuts

The draft guidance for palbociclib and ribociclib means that an estimated 8, 000 women will be eligible to receive the new drugs, which in trials have been shown to slow the ... By postponing disease progression, palbociclib and ribociclib may reduce the

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Latest appointments

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writers: Competitive Salary and Benefits

Account Director: Excellent benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Director, Market Access & HEOR – North-West: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

Associate Editorial Director – Med Comms – London: Salary TBC

Medical/ Scientific Director: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Executive, London, Medical Communications: Excellent package

Senior Medical Writer: Competitive Salary

Senior Medical Writer: Great salary and benefits

New Business Director - PR: Competitive Salary and benefits

Scientific Director / Editorial Team Leader: Great salary and benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Director: £48, 000 - £60, 000

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Account Manager: Negotiable

Medical Writers Required – Cheshire: DOE

Senior Medical Writer (Remote Working): Competitive Salary Offered

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...